MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced updates to its Retina Scientific Advisory Board (SAB) and Executive Leadership Team to enhance external guidance from key opinion leaders and strengthen the Company’s internal expertise in critical functions and as it pursues its goal of three BLAs in the next three years. “As our novel modifier gene therapy programs ...

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:Cadiz (CDZI) acquires and develops water-related land and agricultural assets. The Zacks Consensus Estimate for its current year earnings has been revised 40% downward over the last 60 days.ArriVent BioPharma, Inc. (AVBP) is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The Zacks Cons ...

NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections now recommend monoclonal antibodies for pre-exposure prophylaxis against COVID-19 in appropriate cancer populationsReflects growing alignment among NCCN, IDSA, and CDC on the role of monoclonal antibodies in protecting immunocompromised individuals from COVID-19New data published online in JAMA Oncology from the National Cancer Institute COVID-19 in Cancer Patients Study showed COVID-19 had a signific ...

CHATHAM, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that Tonix Medicines, Inc., its commercial subsidiary, launched the Move Fibro Forward campaign to bring awareness and support to individuals impacted by fibromyalgia, a debilitating condition with no new FDA-approved treatments in over 15 years. “Millions of individuals impacted by fibromyalgia have suffered in silence for far too long,” said Thomas ...

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced compelling immunologic findings from the treatment of a moderate Alzheimer's Disease (AD) patient with intranasal foralumab. Transcriptional analysis of white blood cells before and after foralumab th ...

AI基金中海医药混合A（000878）披露2025年二季报，第二季度基金利润1994.81万元，加权平均基金份额本期利润0.1045元。报告期内，基金净值增长率为 9.21%，截至二季度末，基金规模为2.3亿元。 该基金属于灵活配置型基金，长期投资于医药医疗股票。截至7月18日，单位净值为1.386元。基金经理是梁静静，目前管理2只基金近一年均为正收益。其 中，截至7月18日，中海医药混合A近一年复权单位净值增长率最高，达31.62%；中海医疗保健主题股票A最低，为14.88%。 基金管理人在二季报中表示，投资方向上，聚焦创新药、创新医疗器械及消费升级驱动的医疗服务领域，挖掘成长潜力与估值水平相匹配的优质个股，同时 关注院内（药品、器械、设备等）复苏及场景消费医疗复苏相关个股。本基金坚持自下而上的选股策略，在持续持有优质资产的基础上，深入挖掘被错杀的 底部品种，通过均衡配置降低组合波动，力求为投资者带来长期稳定的收益回报。 截至7月18日，中海医药混合A近三个月复权单位净值增长率为23.97%，位于同类可比基金79/138；近半年复权单位净值增长率为34.70%，位于同类可比基 金81/138；近一年复权单位 ...

CAMBRIDGE, Mass., July 21, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the first patient has been dosed in ALKAZAR, the company's global Phase 3 randomized, controlled trial evaluating neladalkib for TKI-naïve patients with advanced ALK-positive non-small cell lung cancer (NSCLC), versus ALECENSA® (alectinib), a front-line standard of care." ...

The biotech veteran was involved in the development of several approved drugs, likely making him a reassuring choice for a pharmaceutical industry that’s facing pressure from the Trump administration to lower prices and move drug manufacturing to the US https://t.co/ZnLX4JBobH ...

ORION CORPORATION PRESS RELEASE 21 JULY 2025 at 10:30 EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC).Approval is based on positive results from the pivotal Phase III ARANOTE trial.This broadened indication allows doctors to use darolutamide plus ADT, with or without chemothera ...

The pivotal phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every two weeksThe phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeksThe safety profile of astegolimab was consistent with previously reported data, with no new safety signals identifiedAnalysis of the ALIENTO and ARNASA data will be discussed with regulatory ...